Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 45 Pages
|Abilify(重度憂鬱症)- 預測與市場分析 Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023|
|出版日期: 2014年05月30日||內容資訊: 英文 45 Pages||
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Abilify (aripiprazole) is an atypical antipsychotic indicated for use as an adjunctive treatment for MDD in patients who have not adequately responded to antidepressant therapy in the US. Abilify is available in the 5EU, Japan, and Australia, but is not indicated for the treatment of MDD, and as such, it is being used as an off-label treatment, as validated by GlobalData's primary research survey in January 2014.